| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
PharmaSserv is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tanabe Research Laboratories U.S.A., Inc. (TRL), is a wholly owned subsidiary of Tanabe Seiyaku Co., Ltd., headquartered in Osaka, Japan. The Research staff of TRL are highly skilled in biology and/or chemistry and at working in a collaborative
Growve is a company that specializes in acquiring, operating, and growing world class brands in the supplements & active nutrition, beauty & personal care, home & leisure, lifestyle foods, and pet care verticals.
Groupe Parima is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.